EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Troponin Elevation in Patients Undergoing Percutaneous Hepatic Perfusion for Metastatic Uveal Melanoma

Sanjay Chandrasekhar, Matthew Perez, Zurain Niaz, Jahanzaib Ekram, Neelam Lal, Sarah Koly, Biwei Cao, Jonathan S Zager, Mohammed Alomar iD

Cancer Control · 2024

DOI: 10.1177/10732748241246898 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Control, 2024. Verfasst von Sanjay Chandrasekhar und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Sciences, Morsani College of Medicine, University of South Florida, Tampa, FL, USA. Hauptthemen laut MEDLINE: Melphalan, Liver Neoplasms, Melanoma, Uveal Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Delcath Systems, Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Percutaneous Hepatic Perfusion (PHP) is a liver directed regional therapy recently FDA approved for metastatic uveal melanoma to the liver involving percutaneous isolation of liver, saturation of the entire liver with high-dose chemotherapy and filtration extracorporeally though in line filters and veno-venous bypass. The procedure is associated with hemodynamic shifts requiring hemodynamic support and blood product resuscitation due to coagulopathy.

Objective

To assess the cardiac safety and subsequent clinically significant sequalae of this therapy.

Methods

Consecutive PHP procedures done at our center between 2010-2022 were assessed retrospectively. Cardiac risk factors, post procedural cardiac enzymes, electrocardiograms, and transthoracic echocardiograms along with 90-day cardiac outcomes were reviewed. All data were reviewed by cardio-oncologists at our institution.

Results

Of 37 patients reviewed, mean age was 63 years and 57% were women. 132 procedures were performed with an average of 3.57 procedures per patient. 68.6% of patients had elevated troponin during at least 1 procedure. No patients were found to have acute coronary syndrome, heart failure, unstable arrhythmias, or cardiac death. No patients had notable echocardiographic changes. 10.8% of patients with positive troponin had asymptomatic transient electrocardiographic changes not meeting criteria for myocardial infarction. One patient had non-sustained ventricular tachycardiac intra-operatively which did not recur subsequently. Three patients died from non-cardiac causes within 90-days. There was no oncology treatment interruption, even in those with troponin elevation. In multivariable analysis, a history of hyperlipidemia was a predictor of postoperative troponin elevation. ( P = .042).

Conclusion

Percutaneous Hepatic Perfusion is safe and associated with a transient, asymptomatic troponin elevation peri-operatively without major adverse cardiac events at 90 days. The observed troponin elevation is likely secondary to coronary demand-supply mismatch related to procedural hemodynamic shifts, hypotension, and anemia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelphalanLiver NeoplasmsMelanomaUveal NeoplasmsHumansFemaleMiddle AgedMaleAntineoplastic Agents, AlkylatingRetrospective StudiesChemotherapy, Cancer, Regional PerfusionNeoplasm Recurrence, LocalPerfusionUveal Melanoma

Stichwörter der Autor:innen

cardiotoxicityliver metastasesmelphalan

Substanzen

MelphalanAntineoplastic Agents, Alkylating

Autor:innen und Institutionen

  • Division of Cardiovascular Sciences, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.
  • Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
  • Department of Cardio-Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
  • Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
  • Department of Oncologic Sciences, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.

ORCID-Profile: Mohammed Alomar

Förderung

  • Delcath Systems, Inc

Zitieren

APA

Chandrasekhar, S., Perez, M., Niaz, Z., Ekram, J., Lal, N., Koly, S., Cao, B., Zager, J. S., & Alomar, M. (2024). Troponin Elevation in Patients Undergoing Percutaneous Hepatic Perfusion for Metastatic Uveal Melanoma. Cancer Control. https://doi.org/10.1177/10732748241246898

Vancouver

Chandrasekhar S, Perez M, Niaz Z, Ekram J, Lal N, Koly S, et al. Troponin Elevation in Patients Undergoing Percutaneous Hepatic Perfusion for Metastatic Uveal Melanoma. Cancer Control. 2024. doi:10.1177/10732748241246898

BibTeX
@article{Chandrasekhar2024,
  author = {Chandrasekhar, Sanjay and Perez, Matthew and Niaz, Zurain and Ekram, Jahanzaib and Lal, Neelam and Koly, Sarah and Cao, Biwei and Zager, Jonathan S and Alomar, Mohammed},
  title = {Troponin Elevation in Patients Undergoing Percutaneous Hepatic Perfusion for Metastatic Uveal Melanoma},
  journal = {Cancer Control},
  year = {2024},
  doi = {10.1177/10732748241246898}
}
Kostenlos starten →